- Home
- BHE vs IMCR Comparison
BHE vs IMCR Comparison
Compare BHE & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHE
- IMCR
- Stock Information
- Founded
- BHE 1979
- IMCR 2008
- Country
- BHE United States
- IMCR United Kingdom
- Employees
- BHE N/A
- IMCR N/A
- Industry
- BHE Electrical Products
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BHE Technology
- IMCR Health Care
- Exchange
- BHE Nasdaq
- IMCR Nasdaq
- Market Cap
- BHE 1.4B
- IMCR 1.4B
- IPO Year
- BHE 1990
- IMCR 2021
- Fundamental
- Price
- BHE $38.38
- IMCR $29.43
- Analyst Decision
- BHE Strong Buy
- IMCR Buy
- Analyst Count
- BHE 3
- IMCR 12
- Target Price
- BHE $43.00
- IMCR $63.00
- AVG Volume (30 Days)
- BHE 579.0K
- IMCR 418.9K
- Earning Date
- BHE 04-30-2025
- IMCR 05-07-2025
- Dividend Yield
- BHE 1.77%
- IMCR N/A
- EPS Growth
- BHE N/A
- IMCR N/A
- EPS
- BHE 1.72
- IMCR N/A
- Revenue
- BHE $2,656,105,000.00
- IMCR $310,202,000.00
- Revenue This Year
- BHE $4.55
- IMCR $20.52
- Revenue Next Year
- BHE $7.17
- IMCR $8.57
- P/E Ratio
- BHE $22.31
- IMCR N/A
- Revenue Growth
- BHE N/A
- IMCR 24.36
- 52 Week Low
- BHE $28.64
- IMCR $27.19
- 52 Week High
- BHE $52.57
- IMCR $64.47
- Technical
- Relative Strength Index (RSI)
- BHE 41.45
- IMCR 49.49
- Support Level
- BHE $39.74
- IMCR $28.00
- Resistance Level
- BHE $41.55
- IMCR $30.50
- Average True Range (ATR)
- BHE 1.11
- IMCR 1.49
- MACD
- BHE -0.09
- IMCR 0.02
- Stochastic Oscillator
- BHE 23.74
- IMCR 39.29
About BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and advanced manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.